📊 CPHI Key Takeaways
Investment Thesis
China Pharma Holdings exhibits severe financial distress with negative profitability across all metrics, collapsing revenue (-35.4% YoY), and critical liquidity constraints (0.35x current ratio). The company is burning cash operationally while carrying substantial debt, with no operational improvements or insider confidence evident in recent activity.
CPHI Strengths
- Modest asset base of $15.8M provides some liquidation value
- Debt-to-equity ratio of 0.52x is relatively moderate given financial distress
- Active SEC reporting maintains transparency on deteriorating fundamentals
CPHI Risks
- Severe cash burn with negative operating cash flow (-$3.7K) and negative free cash flow (-$62.6K) threatens solvency within months
- Critical liquidity crisis with current ratio of 0.35x and only $267.6K cash against $7.5M liabilities creates immediate insolvency risk
- Revenue collapse of 35.4% YoY combined with negative gross margin (-9.7%) indicates fundamental business deterioration with no path to profitability
- Negative interest coverage (-100.0x) demonstrates inability to service debt obligations
- Zero insider Form 4 filings in 90 days suggests loss of management confidence
Key Metrics to Watch
- Monthly cash burn rate and remaining cash runway
- Quarterly revenue trends and gross margin recovery
- Debt covenant compliance and refinancing requirements
- Insider buying activity as confidence indicator
CPHI Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CPHI Profitability Ratios
CPHI vs Healthcare Sector
How CHINA PHARMA HOLDINGS, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CPHI Balance Sheet & Liquidity
CPHI 5-Year Financial Trend
5-Year Trend Summary: CHINA PHARMA HOLDINGS, INC.'s revenue has declined by 36% over the 5-year period, indicating business contraction. The most recent EPS of $-0.91 indicates the company is currently unprofitable.
CPHI Growth Metrics (YoY)
CPHI Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $756.2K | -$528.4K | $-0.17 |
| Q2 2025 | $924.9K | -$528.4K | $-0.16 |
| Q1 2025 | $1.1M | -$785.6K | $-0.24 |
| Q3 2024 | $1.1M | -$476.0K | $-0.06 |
| Q2 2024 | $924.9K | -$476.0K | $-0.09 |
| Q3 2023 | $1.8M | -$476.0K | $-0.06 |
| Q2 2023 | $1.1M | -$593.0K | $-0.06 |
| Q1 2023 | $1.6M | -$476.0K | $-0.06 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CPHI Capital Allocation
CPHI SEC Filings
Access official SEC EDGAR filings for CHINA PHARMA HOLDINGS, INC. (CIK: 0001106644)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CPHI
What is the AI rating for CPHI?
CHINA PHARMA HOLDINGS, INC. (CPHI) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CPHI's key strengths?
Modest asset base of $15.8M provides some liquidation value. Debt-to-equity ratio of 0.52x is relatively moderate given financial distress.
What are the risks of investing in CPHI?
Severe cash burn with negative operating cash flow (-$3.7K) and negative free cash flow (-$62.6K) threatens solvency within months. Critical liquidity crisis with current ratio of 0.35x and only $267.6K cash against $7.5M liabilities creates immediate insolvency risk.
What is CPHI's revenue and growth?
CHINA PHARMA HOLDINGS, INC. reported revenue of $2.9M.
Does CPHI pay dividends?
CHINA PHARMA HOLDINGS, INC. does not currently pay dividends.
Where can I find CPHI SEC filings?
Official SEC filings for CHINA PHARMA HOLDINGS, INC. (CIK: 0001106644) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CPHI's EPS?
CHINA PHARMA HOLDINGS, INC. has a diluted EPS of $-0.57.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.